Langner K, Müller K M, Junker K
Institut für Pathologie an den Berufsgenossenschaftlichen Kliniken Bergmannsheil, Universitätsklinik Bochum.
Pathologe. 2000 Sep;21(5):358-63. doi: 10.1007/s002920000398.
We reexamined biopsy and resection specimens from seven patients with histologically established primary diagnosis of small-cell lung cancer (SCLC) which showed previously undetected adenocarcinomatous differentiation after chemotherapy. Adenocarcinoma was diagnosed in the same part of the lung as was SCLC before treatment in five cases and in contralateral location in two. Two tumors showed heterogeneous differentiation with small-cell and adenocarcinomatous components, and five had only adenocarcinoma. The interval between histological evidence of SCLC and adenocarcinoma was 3 months-5 years. From the specific findings in the respective patients we can offer two possible explanations for changing differentiation in SCLC after chemotherapy: (a) a primarily heterogeneously differentiated tumor with selection of adenocarcinomatous component under chemotherapy, and (b) an independently developed adenocarcinoma after successful chemotherapy of SCLC, as patients with treated SCLC are known to have an increased risk of non-SCLC. However, therapy-induced alteration of differentiation seems much more unlikely. These findings should be considered in diagnosis and therapy of SCLC to allow early and appropriate reaction to non-SCLC components.
我们重新检查了7例经组织学确诊为小细胞肺癌(SCLC)的患者的活检和切除标本,这些标本显示化疗后出现了先前未检测到的腺癌分化。5例腺癌在治疗前与SCLC位于肺的同一部位,2例位于对侧。2例肿瘤表现为小细胞和腺癌成分的异质性分化,5例仅为腺癌。SCLC和腺癌的组织学证据之间的间隔为3个月至5年。根据各患者的具体发现,我们可以对化疗后SCLC分化改变提出两种可能的解释:(a)一种主要为异质性分化的肿瘤,在化疗下腺癌成分被选择出来;(b)SCLC成功化疗后独立发生的腺癌,因为已知接受治疗的SCLC患者患非SCLC的风险增加。然而,治疗引起的分化改变似乎更不太可能。在SCLC的诊断和治疗中应考虑这些发现,以便对非SCLC成分做出早期和适当的反应。